吡啶-3-磺酰氯盐酸盐 | 42899-76-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 吡啶-3-磺酰氯盐酸盐
• 中文别名: 3-砒啶磺酰氯盐酸盐；3-吡啶磺酰氯盐酸盐
• 英文名称: pyridine-3-sulfonyl chloride hydrochloride
• 英文别名: 3-pyridinesulfonyl chloride hydrochloride；pyridine-3-sulphonyl chloride hydrochloride；pyridine-3-sulfonyl chloride;hydrochloride
• CAS: 42899-76-3
• 化学式: C₅H₄ClNO₂S*ClH
• mdl: MFCD04035552
• 分子量: 214.072
• InChiKey: VIVPWOMJFLICOZ-UHFFFAOYSA-N

物化性质

• 熔点：
  120-126
• 闪点：
  >110℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S22,S26,S30,S36/37/39,S45,S8
• 危险类别码：
  R14,R29,R34
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  存储温度应低于-20°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Pyridinesulfonyl chloride, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P310: Immediately call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Pyridinesulfonyl chloride, HCl
CAS number: 42899-76-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H4ClNO2S.HCl
Molecular weight: 214.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN1759 Class: 8 Packing group: II
Proper shipping name: CORROSIVE SOLIDS, N.O.S. (3-Pyridinesulfonyl chloride, HCl)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吡啶-3-磺酰氯盐酸盐 在 sodium hydride 、 15-冠醚-5 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以93%的产率得到5-(2-fluorophenyl)-4-iodo-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde
  参考文献：
  名称：

  Acid secretion inhibitor

  摘要：

  本发明提供一种具有优越的抑制酸分泌作用并显示抗溃疡活性等的化合物。本发明提供一种由式(I)表示的化合物，其中R1是一种含氮的单环杂环基，可选择地与苯环或杂环缩合，该含氮的单环杂环基可选择地与苯环或杂环缩合，可选择地具有取代基，R2是可选择地取代的C6-14芳基，可选择地取代的噻吩基或可选择地取代的吡啶基，R3和R4分别是氢原子，或者R3和R4中的一个是氢原子，另一个是可选择地取代的较低烷基基团、酰基、卤原子、氰基或硝基，R5是烷基或其盐。

  公开号：

  US20070060623A1
• 作为产物：
  描述：

  3-吡啶磺酸 在 五氯化磷 作用下， 反应 2.0h， 生成 吡啶-3-磺酰氯盐酸盐
  参考文献：
  名称：

  3-磺酰基-1-氨基-1-去硫脑。

  摘要：

  1-carba-1-dethiacephalosporin框架的稳定性已允许在头孢烯领域合成因各种原因而无法使用的一系列3-磺酰基-1-carba-1-dethiacephems。已知的对硝基苄基7β-（苯氧基乙酰胺基）-3-[[（（三氟甲基）磺酰基]氧基] -1-咔基-1-dethia-3-cephem-4-羧酸盐用作该系列化合物的前体。在乙腈或DMF中用各种亚磺酸盐置换烯醇三氟甲磺酸酯，并对中间体进行脱保护，得到7β-[（2-氨基-4-噻唑基）（甲氧基亚氨基）乙酰基]氨基]-3- [烷基（芳基）磺酰基]- 1-carba-1-dethia-3-cephem-4-羧酸。3-磺酰基-1-carba-1-dethiacephems对革兰氏阳性菌和革兰氏阴性菌均显示有效的活性。以下是3-环丙基砜的MIC（微克/ mL）：金黄色葡萄球菌= 4，化脓链球菌= 1，流感嗜血杆菌= 0.25，大肠杆菌=

  DOI：

  10.1021/jm00131a005
• 作为试剂：
  描述：

  {3-[(4-tert-butyl-benzylamino)-methyl]-phenoxy}acetic acid tert-butyl ester 、 吡啶-3-磺酰氯盐酸盐 在 吡啶-3-磺酰氯盐酸盐 作用下， 生成 {3-[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy acetic acid tert-butyl ester
  参考文献：
  名称：

  Prostaglandin agonists and their use to treat bone disorders

  摘要：

  本发明涉及前列腺素激动剂，使用这种前列腺素激动剂的方法，含有这种前列腺素激动剂的药物组合物以及含有这种前列腺素激动剂的套件。这种前列腺素激动剂对于治疗骨疾病，包括骨质疏松症，非常有用。

  公开号：

  US06498172B1

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists
  作者：Martin Cooper、Antonio Llinas、Peter Hansen、Moya Caffrey、Asim Ray、Stina Sjödin、Igor Shamovsky、Hiroki Wada、Tina Jellesmark Jensen、Ulf Sivars、Leif Hultin、Ulf Andersson、Sara Lundqvist、Karin Gedda、Lisa Jinton、Nina Krutrök、Richard Lewis、Paul Jansson、Cristina Gardelli

  DOI：10.1021/acs.jmedchem.0c00828

  日期：2020.9.10

  adipogenesis and therefore has been considered a promising therapeutic target for catabolic conditions. We previously reported on the synthesis and properties of an indane based series of ghrelin receptor full agonists which led to a sustained increase of insulin-like growth factor-1 in a dog pharmacodynamic study. Herein we report on the identification of a series of pyrrolidine or piperidine based

  肌肉萎缩和恶病质是罹患癌症，慢性阻塞性肺疾病和其他几种慢性疾病的患者中的常见合并症。肽激素生长激素释放肽发挥多效性作用，包括刺激生长激素分泌和随后增加胰岛素样生长因子-1水平，这是肌肉生长和修复的重要介质。Ghrelin还作用于炎症，食欲和脂肪形成，因此被认为是分解代谢疾病的有希望的治疗靶标。我们先前曾报道过基于茚满的系列生长素释放肽受体完全激动剂的合成和性质，该合成和性质在狗药效学研究中导致胰岛素样生长因子-1的持续增加。
• [EN] HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES<br/>[FR] HÉTÉRO-1,5,6,7-TÉTRAHYDRO-4H-INDOL-4-ONES
  申请人：BAYER PHARMA AG

  公开号：WO2017102649A1

  公开（公告）日：2017-06-22

  Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.

  本文件所述的式(I)化合物、其制备方法以及作为药物的用途。
• [EN] 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-AMINO-INDOLE 3-SUBSTITUÉS
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2015198045A1

  公开（公告）日：2015-12-30

  The present invention provides compounds of formula (I) (Formula (I)) and pharmaceutically acceptable salts thereof, wherein Q, X% X4,X5 X6, X7,R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.

  本发明提供了公式(I)（公式(I)）的化合物及其药用可接受的盐，其中Q，X，X4，X5，X6，X7，R1，R2，R3和R8如说明书中所定义，这些化合物的制备方法，包含它们的药物组合物以及这些化合物在治疗中的用途。
• [EN] BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013774A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  公开了公式(I)至(VIII)的化合物：(I) (II) (III) (IV) (V) (VI) (VII) (VIII)；或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中R3是与0至3个R3a取代的双环杂芳基团；且R1、R2、R3a、R4和n在此定义。还公开了使用这些化合物作为PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物用于抑制或预防血小板聚集，用于治疗血栓栓塞障碍或作为血栓栓塞障碍的初级预防。